Sarah B Goldberg MD, MPH

Assistant Professor of Medicine (Medical Oncology)

Specialties & Subspecialties

Cancer Center, Yale: Thoracic Oncology Program

Medical Oncology

Education & Training

  • M.P.H., Harvard School of Public Health
  • M.D., Mount Sinai School of Medicine (2006)
  • Resident, Massachusetts General Hospital , Internal Medicine (2006 - 2009)
  • Fellow, Dana-Farber Cancer Institute, Massachusetts General Hospital , Medical Oncology (2009 - 2012)

Patient Care

Accepts New Patients? Yes | Patient Type: Adult | Accepts referrals from patients

Clinical Interests

Lung Cancer; Thoracic Oncology; Personalized Medicine

Cancers Treated

Lung, Mesothelioma, Thymomas

Board Certifications

  • Hematology (Internal Medicine), Board Eligible
  • Internal Medicine, Board Certified (2009)
  • Medical Oncology, Board Certified (2012)

Clinical Trials

ConditionsStudy Title
LungLung Cancer Mutation Consortium Protocol
LungA Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects With Advanced Non-Small Cell Lung Cancer
LungPhase 1b/2, Multicenter, Open-label Study of Carfilzomib, Carboplatin, and Etoposide in Subjects with Previously Untreated Extensive-stage Small-cell Lung Cancer
Bladder, Breast - Female, Lung, Pancreas, and StomachA Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
LungA Phase 1b/2 Study of OMP-59R5 in Combination with Etoposide and Platinum Therapy in Subjects with Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE: Phase 1b/2 INvestigation of anti-Notch Antibody Therapy with Cisplatin and Etoposide in Small Cell Lung Carcinoma Safety and Efficacy)

More Clinical Trials...

Edit Profile